Time frames in this sector can stretch out for a very long time....

Time frames in this sector can stretch out for a very long time. Look at CUV. When this company was floated over 1n 2001 I think the time frame for product to market was only 3 or 4 years and the then CEO was paid $225k. Fourteen years later and the company has finally got the product to market but only for a limited condition and is still not cash flow positive and the current CEO is paid over $1 million.

In the case of ACR the company is profitable pays a great dividend and the CEO is not grossly overpaid. I see no reason why with another good quarter of sales though Lilly that we should not see $1 within a short period of time. I have recently been a buyer at these levels.